Purpose Of Review: The goal of this review is to summarize the recent literature linking HIV to metabolic dysfunction-associated steatotic liver disease (MASLD). This is a pressing issue due to the scale of the MASLD epidemic and the urgent need for preventive and therapeutic strategies for MASLD in PWH.
Recent Findings: The prevalence of MASLD in PWH is higher than previously appreciated, approaching 50% depending on the population and definition of MASLD. MASLD in PWH is likely multifactorial due to risk factors present in the general population such as metabolic syndrome, and features unique to HIV including systemic inflammation and ART. Statin therapy results in a significant reduction in major adverse cardiovascular events in PWH. PWH are at high risk for MASLD. Screening PWH with metabolic syndrome features could enable earlier interventions to reduce morbidity and mortality associated with MASLD in PWH.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11904-023-00669-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- Study aimed to explore how common liver steatosis (LS) and liver fibrosis (LF) are among people with HIV, and what factors contribute to these liver conditions.
- In a large cohort study involving over 4,600 people, it was found that 28% showed signs of LS, with this prevalence increasing to 55% in a group with higher cardiovascular risk factors; LF was less common, affecting only about 1-5% across different assessment methods.
- Key factors linked to LS included current CD4 counts and conditions like diabetes and hypertension, while past use of certain HIV drugs was linked to LF; notably, current treatment with integrase strand transfer inhibitors appeared protective against LF.
MASLD in persons with HIV is associated with high cardiometabolic risk as evidenced by altered advanced lipoprotein profiles and targeted metabolomics.
Lipids Health Dis
October 2024
Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, 702 Rotary Circle, Indianapolis, Indianapolis, IN, 46202, USA.
Background: Metabolic dysfunction associated steatotic liver disease (MASLD) is associated with increased cardiovascular disease (CVD) risk in persons with HIV (PWH). The lipidomic and metabolomic alterations contributing to this risk are poorly understood. We aimed to characterize the advanced lipoprotein and targeted metabolomic profiles in PWH and assess if the presence and severity of MASLD influence these profiles.
View Article and Find Full Text PDFMASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls.
Aliment Pharmacol Ther
November 2024
Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in people with HIV (PWH). The morphological spectrum of MASLD compared to matched controls and of the correlation between the NAFLD activity score (NAS) and fibrosis stage in PWH remains unknown.
Methods: Overall, 107 liver biopsies from PWH with MASLD (MASLD-PWH) were matched to 107 biopsies from individuals with MASLD and without HIV (MASLD controls) on age at biopsy, race/ethnicity, sex, type 2 diabetes, body mass index (BMI) and alanine aminotransferase (ALT) level.
Background: Semaglutide, a GLP-1 receptor agonist, is highly effective for decreasing weight. Concomitant loss of muscle mass often accompanies weight loss and may have consequences on muscle function.
Methods: This is a secondary analysis from the SLIM LIVER (ACTG A5371) study, a single-arm study of semaglutide in people with HIV (PWH) with metabolic dysfunction-associated steatotic liver disorder (MASLD).
The effect of weight gain and metabolic dysfunction-associated steatotic liver disease on liver fibrosis progression and regression in people with HIV.
AIDS
July 2024
Division of Gastroenterology and Hepatology, McGill University Health Centre.
Objective: People with HIV (PWH) have high risk of liver fibrosis. We investigated the effect of weight gain and metabolic dysfunction-associated steatotic liver disease (MASLD) on liver fibrosis dynamics.
Design: Multicenter cohort study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!